Pharmaceutical organizations spend between 4-12% of their annual revenue on patient support services (PSPs) and between $3M-$30M on patient co-pay buy down. For emerging biopharma (EBP), the upfront investment and the opportunity cost relative to perceived other commercial priorities often forces trade-offs on program design.
Please join our panelists as we discuss:
Susan Kitlas
Vice President, Pre-Commercial Sales, IQVIA
Adam Sohn
Vice President, Patient Engagement and New Commercial Model Digital, IQVIA
Kristina Jones
Principal, Patient Engagement, IQVIA
Jennifer Millard
Vice President, Patient Support Services, IQVIA
Deploy sales representatives, clinical nurse educators, field reimbursement specialists virtually or in the field to communicate the benefits of your therapy.